Environment
Mixed / Neutral
Benefits
- no identified direct impact
Risks
- no identified direct impact
Rep. Scott Peters (D-CA)
H.R. 9599 status: Referred.

Official summary alongside an AI-generated read on where it stands and why.
Overall Score
Earlier scoring method. Reanalyze to use the sector calculation.
Bill summary
The bill fundamentally restructures the 340B drug discount program, affecting billions of dollars in drug spending, operational requirements for thousands of hospitals, and the compliance landscape for manufacturers and pharmacy benefit managers.
Modeled effects across six domains, estimated from bill text and comparable legislation.
Mixed / Neutral
Mixed / Neutral
Positive outlook
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Not scored in this analysis.
Generate analysis again to evaluate this sector.
Sourcing already shown above, this is what the analysis found worth flagging.
Confidence
High
Information is complete and verified.
Analysis basis
Full bill text (Congress.gov)
Source used for this bill's analysis.
Warning
increased regulatory reporting and audit requirements may strain resources of smaller, rural, or underfunded safety-net hospitals
!Analysis scope
long-term impact of new user fee structure on safety-net budgets is unknown

Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.

Contact your representatives
Let them know how you feel about this bill.

Share your view
Join the discussion and see what others are saying.

Track this bill
Stay updated on progress and changes.